An Open-Label Study to Investigate the Efficacy and Safety of Peginesatide in the Treatment of Anemia Caused by Antibody-Mediated Pure Red Cell Aplasia in Patients With Chronic Kidney Disease

Trial Profile

An Open-Label Study to Investigate the Efficacy and Safety of Peginesatide in the Treatment of Anemia Caused by Antibody-Mediated Pure Red Cell Aplasia in Patients With Chronic Kidney Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2016

At a glance

  • Drugs Peginesatide (Primary)
  • Indications Anaemia
  • Focus Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 29 Oct 2016 This trial has been completed in Germany (End date: 2016-10-24), according to European Clinical Trials Database.
    • 27 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 21 Dec 2015 Planned End Date changed from 1 Oct 2015 to 1 Oct 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top